Category Archives: ilmn

Illumina: In The Zone

Since our October 6, 2015 posting about Illumina Inc.  (ILMN), the stock has continued in an overall declining trend as outlined in the chart below.

Continue reading

Illumina Downside Targets

The stock of Illumina Inc. (ILMN) is experiencing some major moves to the downside since peaking in July 2015.  After the high of $242, Illumina has declined -39%.  As a component of the Nasdaq 100 index, we think that ILMN is worth watching to see if it achieves any of the downside targets that are outlined by Edson Gould’s Speed Resistance Lines (SRL).

Continue reading

Illumina Shines After Appearing on Watch List

In yesterday’s note, we outlined what appears to be the conclusion of Sanofi-Aventis’ (SNY) attempt to buy Genzyme (GENZ) in a $20 billion deal that was 7 months in the making. Genzyme was on our October 30, 2009 Nasdaq 100 Watch List before Sanofi-Aventis made the initial offered to buy Genzyme (GENZ) in July of 2010. At the time, the New Low team suggested that because so many of the companies on our Nasdaq 100 Watch List were in the drug sector, there was likely to be acquisitions or merger in the same industry. The alternative reaction is for individual investors to bid the price of the stocks higher.

On our December 19, 2009 Nasdaq 100 Watch List, Genzyme (GENZ) shared a place on the list with Illumina (ILMN) (article here). As mentioned yesterday, the price performance of Illumina (ILMN) since being on our December 19, 2009 Watch List has been amazing. Below is a comparison chart of Illumina (ILMN) and Genzyme (GENZ).



Illumina (ILMN) has managed to increase in value by over 3 times as much as Genzyme in the same period. Even the sweetened offer by Sanofi-Aventis, from $69 a share to $74, is not enough to put a dent in the gap between Illumina’s performance against Genzyme. In mid-January 2010 (article here), we pointed out the strength of Illumina’s reported earnings which pushed up the share of the company 15% in a single day. Purchase of ILMN in mid-January 2010 have overshadowed the rise of Genzyme in its path to acquisition.

For companies that appear on our Dividend or Nasdaq 100 lists, we believe it is only a matter of time before the market recognizes the value. In many instances, even a cursory overview of the company’s financial information using sources like Value Line, Morningstar and Mergent (assuming the worst case scenario) can provide a fair approximation of true worth.

Please revisit New Low Observer for edits and revisions to this post. Email us.

Illumina (ILMN) Shines a Light on Profitability

Today, Illumina Inc. (ILMN) was up 15.82% after announcing stronger than expected earnings. According to Yahoo!Quotes, ILMN "...engages in the development, manufacture, and marketing of integrated systems for the analysis of genetic variation and biological function." Apparently it was a total shock to investors and analysts alike that ILMN had the capacity to pull through with strong earnings.

ILMN was last on our Nasdaq 100 Watch List on December 19, 2009. Not long after ILMN hit our list did it catapult 43.69% in 26 days. It is hoped that followers of this website pay close attention to the companies that are on our Dividend Achiever and Nasdaq 100 Watch Lists. Each list has provided exceptional long term and short term opportunities when using fundamental and technical analysis combined. -Touc

A View on the "Buy Low, Sell High" Concept

As the old investment adage goes, "buy low and sell high." However, the act of buying low has a few complications which hasn't been easily resolved. One problem is knowing when a stock's price is actually at a low price or not. Most people confuse the absolute level of a stock price with being low. For example, if a stock is selling for $2 then a person might think that this is a great price to acquire the shares. However, if $2 is the new high for the price and one year ago the old low was $0.25 then $2 is actually very high.

One way that the New Low Observer (NLO) has managed to isolate whether a stock is at a low price is by waiting until the stock is within 20% of the new low. This approach isn't a cure for what ails the average investor. However, it does allow average market participants the opportunity to investigate quality companies for potential price increases. The new low of a stock automatically implies that value has been created especially if the company in question can survive as a going concern. This is counter to most information coming out of the Wall Street media machine. Typically, analysts on Wall Street recommend stocks that have risen far above the low before initiating coverage on a stock.

While there are 4336 individual stocks that can be bought on American stock exchanges, NLO has determined that there are basically only 383 companies that warrant your attention. The first group of companies are known as the Dividend Achievers (excel list of companies). These 283 companies are tracked by Mergent's based on their ability to increase their dividends every year for over 10 years in a row as a minimum requirement. It goes without saying that these companies pay some kind of dividend with yields that range from over 5% to less than 1%.

The second major group of companies tracked by NLO are the constituents of the Nasdaq 100. In our earlier forms as Dividend Inc. and Arti Invest, we believed that only Dividend Achievers were worth tracking since the dividend payment was verifiable regardless of "accounting" inconsistencies that are commonly found with "other" companies. The performance of this approach has been well documented and proven quite profitable.

However, the reality of the stock market dictates that we widen our perspective on companies that might afford significant opportunity with reduced risk. We, at NLO, decided that the Nasdaq 100 was the next obvious choice. After all, most mutual funds are bound to invest in these companies regardless of their unwillingness to pay dividend income. Additionally, companies in the Nasdaq 100 have solid reputations with higher prospects for growth over the long term.

One recent example of the benefit of tracking and research companies posted on NLO, as opposed to those from the Wall Street media machine, is Stericycle (SRCL). SRCL last appeared on our Nasdaq 100 watch list on October 30th. After being on our watchlist since the July 24th initiation of our website, SRCL has managed to climb from the low of $47.76 to the most recent high of $58. This is an increase of 18% from the July low and 21% from the October low and 11.54% from the breakout above our watch list range of being within 20% of the 52-week low.

NLO can be easily contrasted with the recent short-term buy recommendation placed on SRCL by Zack's Investment Research. In a tiny blurb issued today, Zack's Investment Research indicated that SRCL's stock had been in an oversold state based on the stochastics which indicated or implied that the stock was likely to go higher in the near term.

Unfortunately, offering up information about SRCL long after the stock has risen by at least 18% doesn't serve the small investor. After all, isn't the mantra "buy low, sell high?" It is strange to note that no analysts covering SRCL (in the following link) issued a buy recommendation on the stock after February 2004, even though there has been tremendous opportunities to buy in October 2008, February 2009, May 2009 and October 2009.

SRCL is only one of the companies that has been on the NLO Nasdaq 100 Watchlist that performed exceptionally well after getting off the list. Below are other Nasdaq 100 companies and their performance since getting within 20% of the new low:

It should be noted that the above companies are almost the entire list of companies that have appeared on the Nasdaq 100 Watch List. So far, this implies that quality Nasdaq companies could be investigated for speculative opportunities near the new low. Hopefully this approach can provide a reasonable approach to buying low with the prospect of selling higher. Follow along with us as we continue to investigate the speculative opportunities of the Nasdaq 100. -Touc

Nasdaq 100 Watch List

Below are the Nasdaq 100 companies that are within 20% of the 52-week low. This list is strictly for the purpose of researching whether or not the companies have viable business models or are about to go out of business. These companies are deemed highly speculative unless otherwise noted.

Symbol

Name Price P/E EPS Yield P/B

% from Low

GENZ

Genzyme

48.78

27.81

1.75

N/A

1.68

3.59%

GILD

Gilead

42.83

16.56

2.59

N/A

6.90

5.44%

APOL

Apollo Grp

58.40

15.57

3.75

N/A

7.67

10.63%

CEPH

Cephalon

59.04

16.32

3.62

N/A

2.05

12.35%

ERTS

EA

16.72

N/A

-4.06

N/A

2.02

17.42%

ILMN

Illumina

27.88

38.78

0.72

N/A

3.40

19.71%

BIIB

Biogen

50.07

16.76

2.99

N/A

2.18

19.93%